HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is pleased to announce that Suresh Durgam, MD, has ...
Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025 /PRNewswire/ -- Transneural Therapeutics, Inc. ...
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology ...
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical ...
Central Nervous System (CNS) therapies have significantly progressed in the last decade, propelled by emerging treatment modalities including gene therapies. Neurological indications remain amongst ...
Gossamer Bio has disclosed that it has halted development of GB5121 and terminated all clinical studies of the drug following a partial clinical hold imposed by the FDA after two patients died in a ...
The Company's portfolio expansion initiative is being pursued independently of its existing partnership with Receptor.AI, ...
LAS VEGAS, March 6, 2026 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD), a non-profit organization dedicated to advancing central nervous system drug development, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results